53 results
Page 2 of 3
8-K
EX-1.1
smpymbs45
17 Nov 21
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9:04am
424B5
2p8y qvh4b
17 Nov 21
Prospectus supplement for primary offering
9:02am
424B5
98bl5
15 Nov 21
Prospectus supplement for primary offering
5:24pm
8-K
EX-99.1
4445c6d7gy31x
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
8-K
jepwuqode
27 Oct 20
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
7:17am
8-K
EX-1.1
xwzkht w4ba5ai9nalg
9 Jan 20
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5:22pm
POS AM
EX-1.2
s0m1 0qn2ud
4 Oct 19
Prospectus update (post-effective amendment)
4:59pm